ENGLEWOOD, Colo., April 7 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release ...
TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase. TPN-101 will begin Phase 2 clinical trials to study the effects of TPN-101 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback